Evaluasi Drug Related Problems pada Pasien dengan Diagnosis Vertigo Perifer di Instalasi Rawat Jalan Rumah Sakit Bethesda Yogyakarta

Andreas K. Rendra; Rizaldy T. Pinzon

doi:10.15416/ijcp.2018.7.3.162

Evaluasi Drug Related Problems pada Pasien dengan Diagnosis Vertigo Perifer di Instalasi Rawat Jalan Rumah Sakit Bethesda Yogyakarta

Andreas K. Rendra, Rizaldy T. Pinzon

Abstract

Penyakit vertigo dapat berlangsung beberapa detik, menit hingga beberapa jam, tergantung dari penyebab, jenis serta lama durasi. Gejala yang muncul dapat menurunkan kenyamanan dan produktivitas kerja pasien. Tingginya angka kunjungan pasien ke dokter terkait keluhan vertigo akan memperbesar kemungkinan terjadinya Drug Related Problems (DRPs). Tujuan dari penelitian ini adalah untuk mendeskripsikan karakteristik pasien, gambaran umum pengobatan dan mengindentifikasi DRPs terkait penggunaan obat anti vertigo pada pengobatan pasien vertigo perifer di instalasi rawat jalan Rumah Sakit Bethesda Yogyakarta pada periode Januari–Juni 2016. Penelitian ini merupakan penelitian non-eksperimental deskriptif evaluatif dengan rancangan case series dan menggunakan data retrospektif. Evaluasi penggunaan obat antivertigo dianalisis dengan metode subjective, objective, assessment, plan (SOAP). Data 75 pasien vertigo perifer terdiri dari 28 laki-laki (37%) dan 47 perempuan (63%). Golongan obat antivertigo yang paling banyak diresepkan yaitu golongan histaminergik (97,33%) dan golongan antagonis kalsium (53,33%). Kejadian DRPs yang muncul yaitu obat kurang efektif (10,66%), dosis kurang (36%) serta interaksi dan efek samping (48%).

Kata kunci: DRPs, obat antivertigo, rawat jalan, vertigo perifer

Drug Related Problems Evaluation in Vertigo Perifer Diagnosed at Outpatient Care Bethesda Hospital Yogyakarta

Abstract
Vertigo disease is able to last for a few seconds, minutes to several hours, depends on the cause, type and duration. The symptoms can reduce the patient’s comfort and productivity. High number of patient visitation to physicians related to vertigo will increase the possibility of the occurance of Drug Related Problems (DRPs). The purpose of this study was to describe the characteristics of the patients, general treatment, and identify DRPs related to antivertigo drug in the medical treatment of patients diagnosed with peripheral vertigo at outpatient care Bethesda Hospital in Yogyakarta from January–June 2016. The study employed a non-experimental evaluative descriptive that used case series design and retrospective data. The antivertigo drug use evaluation was analyzed using subjective, objective, assessment, plan (SOAP) method. Data collected from 75 patients diagnosed with peripheral vertigo consisted of 28 men (37%) and 47 women (63%). The group of antivertigo drug which mostly prescribed were histaminergic (97.33%) and calcium antagonists (53.33%). The DRPs found in this study are ineffective drug (10.66%), too low dosage (36%) and also interactions and adverse drug reaction (48%).

Keywords: Antivertigo drug, DRPs, peripheral vertigo, outpatient care

Keywords

DRPs, obat antivertigo, rawat jalan, vertigo perifer

Full Text:

PDF (Bahasa Indonesia)

References

Wahyudi KT. Vertigo. Cermin Dunia Kedokteran. 2012;39(10):738–41.

Grill E, Muller M, Brantdt M, Jahn K. Vertigo and dizziness: Challenges for epidemiological research. OA Epidemiology. 2013;1(2):12.

Chakor RT, Eklare N. Vertigo in cerebrovascular disease. Otolaryngol Clin. 2012;4(1):46–53.

Vaz DP, Gazzola JM, Lança SM, Dorigueto RS, Kasse CA. Clinical and functional aspects of body balance in elderly subjects with benign paroxysmal positional vertigo. Braz J Otorhinolaryngol. 2013;79(2):150–7.

Fitriani DL, Ramatillah AR. Related drug problem in the treatment of vertigo disease and hypertension in PGI Cikini Hospital. Int J Pharm Teaching Pract. 2014;5(3):1020–552.

Cipolle RJ, Syrand LM, Morley PC, Ramsey R, Lamsasam GD. Pharmaceutical care practice: The clinician’s guide. USA: The McGraw-Hill Companies; 2012.

Abes GT, Caro RM, Chiong CM, Carrillo RJ, Yang NW, Chan AL, et al. Clinical practice guidelines vertigo in Adults-2nd Edition. Philippine J Otolaryngology Head Neck Surgery. 2014;2(29):1–16.

Swartz R, Longwell P. Treatment of vertigo. Am Fam Physician. 2005;71(6):1115–21.

MIMS Treatment Guidelines. Treatment guidelines for vertigo [Accessed on: 2 July 2016]. Available at: http://drc.mims.com/Vertigo/Treatment.

Medscape. Drug interaction checker [Accessed on: 25 Mei 2016]. Available at: http://reference.medscape.com/drug-interactionchecker.

Shami I, Al Sanosi A. Causes of vertigo in Saudi patients seen at tertiary teaching hospital. J Taibah Univ Med Sci. 2011; 6(1):27–33. doi: 10.1016/S1658-3612(11)70153-6

Al-Asadi JN, Al-Lami Q. Prevalence and risk factors of benign paroxysmal positional vertigo among patients with dizziness in Basrah, Iraq. Br J Med Med Res 2015;7(9):754–61. doi: 10.9734/BJMMR/2015/16542

Benecke H, Pérez-Garrigues H, Bin Sidek D, Uloziene I, D K, Sondag E, et al. Effect of betahistine on patient-reported outcomes in routine practice in patient with vestibular vertigo and appraisal of tolerability: Experience in the OSVaLD study. Int Tinnitus J. 2010;16(1):14–24.

Yacovino DA, Luis L. Pharmacologic treatment of vestibular disorders. Vestibular Disorders Association. 2014;15(5018):1–8.

Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: A future for subtype-selective GABAA receptor modulators? Adv Pharmacol Sci. 2012;2012:416864. doi: 10.1155/2012/416864

Mosena MS, Merwe EVD. The appropriateness and risks of tablet splitting. SA Pharmaceutical J. 2009;76(7):36.

Albadr Y, Bohassan AK, Ming LC, Khan TM. An exploratory study investigating the potential drug-drug interaction in internal medicine Department Al Ahsa Saudi Arabia. J Pharm Health Serv Res. 2014;5(4):237–41. doi: 10.1111/jphs.12073

DOI: https://doi.org/10.15416/ijcp.2018.7.3.162